Cargando…

Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies

STUDY OBJECTIVE: We evaluated thromboembolic events after vitamin K antagonist reversal in post hoc analyses of pooled data from 2 randomized trials comparing 4-factor prothrombin complex concentrate (4F-PCC) (Beriplex/Kcentra) with plasma. METHODS: Unblinded investigators identified thromboembolic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milling, Truman J., Refaai, Majed A., Goldstein, Joshua N., Schneider, Astrid, Omert, Laurel, Harman, Amy, Lee, Martin L., Sarode, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537597/ https://www.ncbi.nlm.nih.gov/pubmed/26094105 http://dx.doi.org/10.1016/j.annemergmed.2015.04.036

Ejemplares similares

Increased risk of volume overload with plasma compared with four‐factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
por: Refaai, Majed A., et al.
Publicado: (2015)

Four-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding: A Post Hoc Analysis of Two Randomized Controlled Trials
por: Refaai, Majed A., et al.
Publicado: (2017)

Safety of a Four‐factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials
por: Milling, Truman J., et al.
Publicado: (2016)

INR and vitamin K–dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma
por: Hood, Christopher, et al.
Publicado: (2022)

Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals
por: Refaai, Majed A., et al.
Publicado: (2023)

Reversal of Vitamin K Antagonist Therapy by Prothrombin Complex Concentrate before Thrombolysis for Acute Stroke
por: Chausson, Nicolas, et al.
Publicado: (2013)

Efficacy and safety of activated prothrombin complex concentrate for the reversal of vitamin K antagonist major bleeding
por: Sheikh-Taha, Marwan, et al.
Publicado: (2022)

Use of Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal before Surgical Treatment of Intracranial Hemorrhage
por: Wong, Yun
Publicado: (2011)

Optimal Dosage and Administration Practices for Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate
por: Rhoney, Denise H., et al.
Publicado: (2020)

Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding
por: Schick, Kerstin S, et al.
Publicado: (2009)

Safety and efficacy of a strategy of vitamin K antagonist reversal with prothrombin complex concentrates compared to vitamin K in patients with hip fracture
por: Jay-Caillierez, Lucille, et al.
Publicado: (2021)

Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists
por: Müller, Martin, et al.
Publicado: (2019)

Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department
por: Maguire, Michelle, et al.
Publicado: (2019)

Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
por: Milling, Truman J., et al.
Publicado: (2016)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Coagulation Factor Plasma Levels Following Administration of a 4-Factor Prothrombin Complex Concentrate for Rapid Vitamin K Antagonist Reversal in Japanese Patients
por: Yasaka, Masahiro, et al.
Publicado: (2018)

3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis
por: Puchstein, Dorothea, et al.
Publicado: (2023)

Clinical outcome of patients with a vitamin K antagonist‐associated bleeding treated with prothrombin complex concentrate
por: Brekelmans, Marjolein P. A., et al.
Publicado: (2017)

Preclinical and clinical data for factor Xa and “universal” reversal agents(,,)
por: Milling, Truman J., et al.
Publicado: (2016)

Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
por: Milling, Truman J., et al.
Publicado: (2016)

Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding
por: Go, Alan S., et al.
Publicado: (2022)

Prothrombin complex concentrates in warfarin anticoagulation reversal
por: Costa-Lima, Carolina, et al.
Publicado: (2012)

Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation
por: Grottke, Oliver, et al.
Publicado: (2016)

A review of guidelines on anticoagulation reversal across different clinical scenarios – Is there a general consensus?
por: Milling, Truman J., et al.
Publicado: (2020)

Reversal of oral anticoagulation with prothrombin complex concentrate (Octaplex)
por: Riess, H, et al.
Publicado: (2007)

Reduced Time to Procedure for Gastrointestinal Bleeding After Warfarin Reversal With Four-Factor Complex Concentrate as Compared to Plasma
por: Spector, Hannah, et al.
Publicado: (2023)

Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis
por: Abdoellakhan, Rahat Amadkhan, et al.
Publicado: (2016)

Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage
por: Parry‐Jones, Adrian R., et al.
Publicado: (2015)

Venous thromboembolism is caused by prothrombin p.Arg541Trp mutation in Japanese individuals
por: Yamamoto, Jumpei, et al.
Publicado: (2021)

Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma
por: Wang, Xiumei, et al.
Publicado: (2017)

Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice
por: Desmettre, Thibaut, et al.
Publicado: (2012)

The role of prothrombin complex concentrates in reversal of target specific anticoagulants
por: Babilonia, Katrina, et al.
Publicado: (2014)

Evaluation of Prothrombin Response to Vitamin K as Liver Function Test
por: Wahi, P. N.
Publicado: (1947)

Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study)
por: Tazarourte, Karim, et al.
Publicado: (2014)

Four-factor prothrombin complex concentrate (Beriplex® P/N) is superior to three-factor prothrombin complex concentrate for reversal of coumarin anticoagulation
por: Herzog, E, et al.
Publicado: (2015)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma
por: Yang, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_09kljmrkgii7el67dpuod0erb9